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Abstract. – OBJECTIVE: The aim of this quali-
tative review is to provide an update on the cur-
rent understanding of the genetic determinants 
of lipedema and to develop a genetic test to dif-
ferentiate lipedema from other diagnoses. 
MATERIALS AND METHODS: An electronic 
search was conducted in MEDLINE, PubMed, and 
Scopus for articles published in English up to 
March 2019. Lipedema and similar disorders in-
cluded in the differential diagnosis of lipedema 
were searched in the clinical synopsis section of 
OMIM, in GeneCards, Orphanet, and MalaCards.
RESULTS: The search identified several ge-
netic factors related to the onset of lipedema and 
highlighted the utility of developing genetic diag-
nostic testing to help differentiate lipedema from 
other diagnoses.
CONCLUSIONS: No genetic tests or guidelines 
for molecular diagnosis of lipedema are current-
ly available, despite the fact that genetic testing 
is fundamental for the differential diagnosis of li-
pedema against Mendelian genetic obesity, pri-
mary lymphedema, and lipodystrophies.
Key Words:
Lipedema, Lipoedema, Differential diagnosis, Sub-
cutaneous fat, Genetic diagnosis.
Introduction
Lipedema is an underdiagnosed chronic debil-
itating disease characterized by bruising and pain 
and excess of subcutaneous adipose tissue of the 
legs and/or arms in women during or after times 
of hormone change, especially in puberty1. A defi-
nition of lipedema has not yet been included in the 
10th revision of the International Classification of 
Diseases (ICD) by the World Health Organization 
(WHO) although an ICD-11 code of EF02.2 has 
been proposed. The first guidelines on lipedema 
were proposed in 2015 in Germany and by oth-
ers in 2017 using the international classification 
of functioning, disability and health2-4. Lipedema 
coexists frequently with obesity and can be easi-
ly confused with it. However, lipedema is distin-
guishable from obesity because it is located pri-
marily in the lower limbs and upper extremities 
sparing the trunk; lipedema minimally responds 
to diets. Finally, women with lipedema can have a 
normal Body Mass Index (BMI)5. Lipedema can 
be confused with lymphedema. There are sub-
stantial differences between these two diseases: 
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while lipedema is always bilateral, lymphedema 
can be unilateral or bilateral; distinctive features 
of lipedema are pain and bruising that are absent 
in lymphedema; and in lipedema, the Stemmer 
sign is negative6. Furthermore, lipedema may be 
associated with multiple lipomas on the arms and/
or trunk which are not found in lymphedema5,6. 
The prevalence of lipedema has been reported to 
be 1-9/1000007. However, it is notable that epide-
miological data can fail to recognize lipedema or 
include individuals who are misdiagnosed with 
other similar diseases, most commonly obesity, 
lymphedema, and lipodystrophies. Lipedema can 
be considered as one component of a spectrum of 
diseases that are characterized by the dysregu-
lated proliferation of adipose tissue and the pres-
ence of pain. The adiposis dolorosa (painful fat) 
spectrum of diseases includes: 1) “Generalized 
diffuse form of Dercum disease” where painful 
pearl-sized nodular subcutaneous adipose tissue 
is widespread throughout the body without larger 
masses; 2) “generalized nodular form of Dercum 
disease” where larger painful nodules are found 
on the arms, trunk, and thighs; 3) “lipedema”, a 
localized form of painful fat with characteristic 
distribution of pearl-sized nodular fat and larger 
masses on the limbs; 4) “localized nodular form 
of Dercum disease”, usually found around joints 
(juxta-articular type); and 5) “Madelung disease” 
or multiple symmetric lipomatosis with nodular 
fat and lipomas on the upper aspect of the body 
although a “gynoid type” has been identified8,9 
(Figure 1). With a variety of diseases of painful 
fat, diagnosing painful lipedema may be diffi-
cult; it would be useful to develop a genetic test 
that analyses all the genes known for Mendelian 
non-syndromic genetic obesity, primary lymph-
edema, and lipodystrophies when trying to diag-
nose a patient with lipedema, due to the clinical 
findings these diseases hold in common10. This 
review aims to outline current knowledge about 
the genetics of lipedema and highlights the im-
portance of genetic testing for a more precise di-
agnosis of lipedema to separate it from similar 
appearing conditions.
Materials and Methods
This is a “qualitative review” in which, infor-
mation published about lipedema in referenced 
scientific journals until March 2019 were col-
lected. An electronic search was conducted in 
MEDLINE, PubMed and Scopus, using different 
combinations of the search terms and concepts “li-
pedema”, “lipedema genes”,” lipedema etiology”, 
“lipedema differential diagnosis”, “lipedema and 
obesity”, “lipedema and lymphedema”, “lipedema 
and lipodystropy”, “clinical manifestations of li-
pedema” and “lipedema genetic testing”. Articles 
in English were first chosen by examining the title 
and abstract and, subsequently, analyzed by two 
independent readings of the whole text. Reference 
lists were scanned to retrieve other relevant arti-
cles. The reviewers assessed the full-text articles. 
A search for lipedema and similar disorders that 
overlap in the differential diagnoses was con-
ducted in the clinical synopsis section of OMIM, 
GeneCards, Orphanet and MalaCards. Orphanet 
GeneReviews, and Genetic Home Reference were 
searched to find existing genetic diagnostic tests 
for lipedema. A general PubMed research was 
used to investigate clinical, diagnostic and genet-
ic testing guidelines regarding lipedema. Any dis-
agreements were solved through discussion until 
consensus.
Results
Clinical Aspects of Lipedema
Lipedema is a chronic condition of deposits of 
painful fat, primarily in the gynoid region, occurring 
at times of hormone change in women, especially 
at the time of puberty, that causes gait and joint ab-
normalities, and which eventually can result in the 
development of lymphedema, called lipo-lymphede-
ma. Clinically, lipedema has several features: abnor-
mal and painful adipose tissue on the legs, thighs, 
buttocks, and on the arms in 80%, of cases with a 
BMI that can be normal or increased without ab-
dominal obesity11; chronic pain that can significant-
ly impact mobility; joint hypermobility associated 
with fatigue1,12,13; bruising due to increased capillary 
fragility14; edema in advanced stages or longstand-
ing lipedema15 and psychosocial stress and associ-
ated psychiatric disorders, especially anxiety and 
depression16. The main classifications of lipedema 
are Schingale classification (Types I, II, III, IV, and 
V) based on the different distribution of adipose tis-
sue2 and Schmeller and Meier-Vollrath classification 
(Stages I, II, III, and IV) depending on the sever-
ity of the disease12. Conservative treatments of li-
pedema include: manual lymphatic drainage as part 
of complex decongestive therapy, subcutaneous ad-
ipose tissue therapy to reduce fibrosis and increase 
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fluid flow through the tissue, compression garment 
therapy or wrapping to reduce tissue fluid, physical 
activity and healthy food plans to reduce any obesity 
component of lipedema, medical foods and supple-
ments (such as selenium, Butcher’s broom or dios-
min), deep breathing and psychosocial counseling. 
For patients with minimal or no improvement with 
conservative treatment, surgical treatments includ-
ing liposuction and reductive surgery are needed2. 
Lipedema is thought to be either primary (idiopath-
ic, probably genetic) or secondary, associated with 
hormonal disease, connective tissue disorders and/
or autoimmune disease17,18. The long-term effects of 
lipedema on lifespan are not known12.
Etiopathogenesis of Lipedema
Lipedema is a chronic disease of lipid metab-
olism resulting in the symmetrical deposition of 
subcutaneous adipose tissue associated with hy-
perplasia and/or hypertrophy of fat cells19. Etio-
pathogenesis is unclear but may be associated with 
impairment of a hormonal axis, since lipedema 
mainly affects females and its onset is primari-
ly around the time of puberty20. Estrogen has a 
direct effect on adipose tissue through estrogen 
receptors (ERs)21. Rarely, men are affected with 
lipedema. Men who develop lipedema tend to be 
hypogonadal or have liver disease resulting in rel-
atively elevated estrogen levels22. Estrogen may, 
Figure 1. Depiction of phenotypic overlap of different conditions characterized by subcutaneous fat accumulation. 
S. Paolacci, V. Precone, F. Acquaviva, P. Chiurazzi, E. Fulcheri, et al
5584
multidisciplinary approach that evaluates the ge-
nome, the transcriptome, and the methylome.
Syndromic Lipedema
Lipedema may be present within a syndromic 
context. These diseases may be good models to 
determine the molecular pathways potentially in-
volved in isolated non-syndromic lipedema.
Example 1: One report associated a germline 
missense variant, c.196C>T (p.Pro24Leu), in PO-
U1F1A in a family with recurrence of short stature 
and swelling of legs which only affected females 
in four generations of the family. The only male 
found affected did not have a lipedema phenotype, 
only short stature. Affected family members also 
had growth hormone deficiency, secondary hypo-
thyroidism and hypoprolactinemia26. POU1F1A 
encodes Pit-1, a transcription factor specifical-
ly expressed in the anterior pituitary gland, that 
regulates the expression of the growth hormone 
(GH), prolactin (PRL) and thyroid-stimulating 
hormone (TSH) beta-subunit genes27,28.
A pathogenic mutual translocation 46; 
XX; t(10;15) (q25.2;q11.2) (ClinVar ID: 
SCV000320871.1) is associated with various con-
ditions, including lipedema29. The 10q25.2 and 
15q11.2 bands include several genes that are im-
portant for fat metabolism. For instance, changes 
in the chromosomal region 15q11.2, with loss of 
gene activity are associated with specific syn-
dromes, such as Prader-Willi syndrome (PWS), 
characterized by pathologic hyperphagia and 
obesity30. The genes that map in this region may 
be good candidates for the onset of lipedema. This 
is also supported by the observation of one of the 
authors, that report that lipedema is present in 5% 
of PWS patients (personal observation).
Example 2: Sotos syndrome 1 is caused by 
germline mutations in NSD1. A novel missense 
mutation, (p.Cys2175Ser) has been reported in a 
patient with a familial form of Sotos syndrome 
characterized by normal intelligence, insu-
lin-dependent diabetes, bronchial asthma, and 
lipedema. NSD1 encodes a protein that, together 
with associated co-regulators, enhances androgen 
receptor transactivation, therefore it may be part-
ly responsible for the estrogen-mediated lipedema 
tissue growth31.
Example 3: Williams-Beuren syndrome is a 
multi-systemic neurodevelopmental and meta-
bolic disorder. In some cases, lipedema can be 
present17,32. This syndrome is caused by deletion 
of a stretch of 27 genes in the chromosomal region 
7q11.2333 and the best candidates to explain the 
therefore, play a role in the development of fat and 
other tissues that have sex hormone receptors23. 
Almost certainly an altered ER pattern or respon-
siveness exists centrally, not only in the adipose 
tissue, which may provide an additional explana-
tion for difficulties in gynoid and arm fat loss in 
patients suffering from lipedema10,20. Additional 
mechanisms thought to play a role in the patho-
genesis of lipedema include increased vascular 
permeability and damage (microangiopathy), ex-
cessive lipid peroxidation, and disturbances in ad-
ipocyte metabolism and cytokine production20,21. 
In a recent study, cells of the stromal vascular 
fraction (SVF), which includes adipose-derived 
stromal stem and other cells from 30 patients with 
lipedema and 22 controls, were characterized. 
Of note, the yield of stem cells was higher from 
lipedema fat, which might be explained by an 
enhanced expression of the mesenchymal (con-
nective tissue) marker CD90 and the endothelial/
pericytic marker CD146 suggestive of growth. 
These markers specifically suggest there may be 
a chronic capillary injury in lipedema leading to 
an increased need for repair and protection. De-
spite these findings, the SVF is thought to be a 
suitable option for autologous tissue regeneration 
strategies in lipedema patients22. In summary, li-
pedema is a heterogeneous likely genetic disease, 
which manifests in parallel with female hormonal 
changes and leads to vasculo- and lymphangiop-
athy. Inflammation of the peripheral nerves and 
sympathetic innervation abnormalities of the sub-
cutaneous adipose tissue may be responsible for 




Lipedema is thought to be an inherited disease 
in most cases. Self-reported positive family his-
tory of lipedema is found for up to 64% of wom-
en, therefore, a genetic etiology for lipedema is 
strongly suggested10. A possible link between the 
genetic factors and the hormonal role of estrogens 
in the development of lipedema has been hypoth-
esised24. Autosomal dominant inheritance with 
incomplete penetrance and sex limitation (most 
affected female family members) is the most like-
ly mode of inheritance12,25. Lipedema may be dif-
ferentiated into non-syndromic, syndromic and/or 
associated with comorbidities. To date, the gene 
associated with primary isolated lipedema has not 
been identified. For the diagnosis and research of 
the genetic basis of lipedema, it is necessary a 
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been detected in human benign tumors of mesen-
chymal origin, including lipomas42,43.
A rare case of autosomal dominant familial 
multiple subcutaneous lipomatosis (FML) and 
increased predilection to cancers co-segregat-
ing with a novel germline truncating mutation in 
PALB2 (c.2716delT) has been reported44.
Two patients with encephalocraniocutaneous 
lipomatosis, a congenital hamartomatous disor-
der characterized by unilateral skin lesions, lipo-
mas, and ipsilateral ophthamological and cerebral 
malformations, have been found to carry a KRAS 
somatic mutation c.436G>A (p.Ala146Thr) and a 
NF1 de novo germline truncating mutation, re-
spectively44-47.
PIK3CA somatic activating mutations, pre-
viously reported in cancer and overgrowth syn-
dromes, have been discovered in the affected 
tissue of individuals with facial infiltrating lipo-
matosis48. The syndrome of multiple symmetric 
lipomatosis, partial lipodystrophy and insulin re-
sistance is caused by germline mutations in LIPE. 
These mutations result in marked inhibition of li-
polysis from adipose tissue depots49 which could 
explain fat expansion in lipedema.
The Pierpont syndrome, a plantar lipoma-
tosis with limb abnormalities, unusual facies 
and developmental delay is caused by a de novo 
heterozygous missense mutation (p.Tyr446Cys) 
in TBL1XR150. In two cases, two different mu-
tations have been reported p.Cys325Tyr and 
p.Tyr446His51.
Hereditary retinoblastoma is caused by vari-
ants in RB1 (40% of mutations are germline, 
inherited or de novo; 60% of mutations are so-
matic). Retinoblastoma, an embryonic malignant 
neoplasm of retinal origin, is found in association 
with lipomatosis in less than 4% of the affected 
subjects52. Lipomatosis predisposition in hered-
itary retinoblastoma is not associated with spe-
cific RB1 variants but is probably determined by 
modifying factors53. Interestingly, the retinoblas-
toma interacting zinc finger gene RIZ codes for a 
protein that is a downstream effector of estrogen 
action and is involved in an alternative intracel-
lular pathway, mediating the mitogenic effect of 
estradiol54,55, a finding that may be pertinent to 
lipedema.
In support of the hypothesis that multiple sym-
metric lipomatosis is caused by mitochondrial 
mutations10,56, there are several studies. A study 
reported that 32.4% (11/34) of cases affected by 
myoclonic epilepsy with ragged-red fibers (MER-
RF) show the presence of multiple lipomatosis. 
involvement of subcutaneous fat tissue are ELN34, 
FZD935, MLXIPL36.
Example 4: Pseudoxanthoma elasticum (PXE) 
is another syndrome in which lipedema can be 
present. PXE mainly affects skin, eyes, and the 
cardiovascular and gastrointestinal systems and 
patients show a progressive mineralization of 
elastic fibers. Abnormal elastic fibers similar to 
those found in PXE have been observed in skin 
lesions of patients with lipedema; furthermore, 
PXE fibroblasts show an increased cholesterol 
biosynthesis which could be important in the de-
velopment of lipedema fat tissue37. PXE can be 
either autosomal dominant or recessive and is due 
to germline mutations in ABCC6 and a subclinical 
form of PXE has been reported as predisposing 
to lipedema18,38. Although, to date, no mutations 
have been reported in ABCC6, in association with 
lipedema.
Example 5: Cutis laxa type III is a multisys-
tem connective tissue disorder characterized by 
wrinkled, inelastic skin, associated with a neu-
rologic component, retinopathy and the presence 
of abnormal fat pads on the buttocks and upper 
thighs. Cutis laxa type III can be either autosomal 
recessive or dominant and is caused by germline 
mutations in ALDH18A139, a gene that encodes an 
enzyme that catalyzes the reduction of glutamate 
to delta1-pyrroline-5-carboxylate, a critical step 
in the de novo biosynthesis of proline, ornithine, 
and arginine.
One study reports that hypermobility may be 
associated with lipedema; in this report, about 
50% of women with lipedema had joint hyper-
mobility suggesting that they may also have the 
common disorder known as hypermobile Ehlers 
Danlos syndrome (hEDS) formerly hypermobil-
ity type or type III13,21. Germline truncating mu-
tations in TNXB and a single germline variant in 
COL3A1, (p.Gly637Ser) have been found to cause 
the Ehlers-Danlos syndrome type III, to date, no 
mutations have been found in those two genes in 
association with lipedema40,41.
Clinically Overlapping Conditions 
with Lipedema
In thinking about a possible genetic test for 
lipedema, it is important to consider the genes 
mutated in conditions that may be phenotypically 
overlapping or confused with lipedema for differ-
ential diagnosis, such as lipomas or familial mul-
tiple lipomatosis.
For instance, disruption of HMGA2, located 
in the chromosomal band 12q14.3, has frequently 
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with upper body obesity compared to gynoid fat 
deposits, respectively.
FPLD4 is caused by heterozygous truncating 
mutations in PLIN1, encoding perilipin-1. This 
protein covers lipid storage droplets in adipo-
cytes, protecting them until they can be broken 
down by hormone-sensitive lipases. Perilipin-1 is 
the major cAMP-dependent protein kinase sub-
strate in adipocytes and may play a role in the in-
hibition of lipolysis63. The phenotype of women 
with FPLD4 is different from that of women with 
lipedema, with upper body obesity compared to 
gynoid fat deposits, respectively.
FPLD5 has been reported in a single case 
caused by a homozygous truncating mutation in 
CIDEC (p.Glu186*). Perilipin-1 and CIDEC are 
involved in the structure and function of adipo-
cyte lipid droplets63.
FPLD6 is caused by homozygous truncating 
mutations in LIPE, encoding hormone-sensitive 
lipase, which is involved in the regulation of li-
polysis63.
Akt2-linked lipodystrophy was described in a 
single family and is caused by heterozygous mis-
sense mutations in AKT2, which is a key mediator 
of insulin signaling downstream of the insulin re-
ceptor65. The phenotype of women with FPLD6 
is different from that of women with lipedema, 
with upper body obesity compared to gynoid fat 
deposits, respectively.
Familial partial lipodystrophies share common 
phenotypes. The typical loss of fat occurs to the 
buttocks and limbs and a gain of fat to the face, 
neck, and abdomen. Metabolic complications of 
the familial partial lipodystrophies include insu-
lin resistance, diabetes mellitus, hypertriglyceri-
demia, hepatic steatosis, hypertension, and coro-
nary artery disease, none of which correlates with 
the phenotype of lipedema. However, genes im-
portant in partial lipodystrophy may be important 
in modifying the phenotype of lipedema.
In an African-American pedigree with a novel 
autosomal dominant atypical FPLD, Garg et al66 
performed linkage analysis for candidate regions 
and whole-exome sequencing to identify the dis-
ease-causing mutation. The affected individuals 
had marked loss of the fat from the extremities, 
with excess fat in the face and neck, and metabolic 
complications. The authors identified a mutation 
(c.202C>T, p.Leu68Phe) in the adrenoceptor α 2A 
(ADRA2A) in all affected subjects but not in the 
unaffected. ADRA2A regulates norepinephrine 
release and its activation reduces lipolysis in ad-
ipocytes. The mutation p.Leu68Phe presumably 
Of them, only 6 had isolated lipomatosis with no 
myopathic complaints and/or CNS involvement. 
All of these patients carried the m.8344A>G 
mutation in the MTTK, transcripted in the tR-
NALys57-59. In a multigenerational Canadian family 
with 8 affected members, the complete co-segre-
gation of the rare mitochondrial variant in MTTK 
(8344A>G) and the phenotype was reported60.
Multiple symmetric lipomatosis (Madelung 
disease), a rare disorder of adipocyte differentia-
tion characterized by benign, diffuse lipomatosis 
in the cephalic, cervical, and upper thoracic sub-
cutaneous depots, can carry biallelic mutations in 
MFN2, a gene encoding a mitochondrial protein 
already associated with Charcot-Marie-Tooth 
syndrome45,61.
Familial Partial Lipodystrophies 
and Lipedema
It is important to point out that in some cases 
of partial lipodystrophy there may be an accumu-
lation of subcutaneous fat tissue in specific depots 
coupled with the reduction of fat in other regions. 
The majority of familial partial lipodystrophy 
(FPLD) syndromes are autosomal dominant. Phe-
notypically, patients with FPLD, type 2 and some 
of the other partial lipodystrophies lack limb and 
gluteal subcutaneous fat, while in FPLD, type 1, 
the abdomen shows weight gain and the limbs and 
buttocks lose fat62. In most cases, body fat redis-
tribution occurs during puberty. Adipose tissue in 
the face, neck and intra-abdominal areas may be 
increased in FPLD, type 2. Diabetes and metabol-
ic complications, such as coronary artery disease, 
occur in adulthood in these disorders63.
FPLD, type 2 is caused by autosomal domi-
nant mutations in LMNA, the most common be-
ing p.Arg482Gln; this gene encodes the nuclear 
lamin A/C protein. Fat loss typically occurs in the 
buttocks and limbs, and gain of fat occurs to the 
face, neck, abdominal viscera, and labia, although 
there is phenotypic variability. Patients may also 
have lipomas63. While lipedema may be misdiag-
nosed as lipodystrophy, the metabolic differences 
between lipedema, which confers low cardiovas-
cular risk, and FPLD, type 2, which confers high 
cardiovascular risk, are clear.
FPLD, type 3 is caused by heterozygous mis-
sense mutations in PPARG. Fat loss usually oc-
curs with loss of fat from the trunk, buttocks, and 
limbs and there is no increase in head and neck 
fat. However, there may be a gain of fat on the ab-
domen63,64. The phenotype of women with FPLD3 
is different from that of women with lipedema, 
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developed obesity on a high-fat diet, with severe 
insulin resistance and hepatic steatosis, which is, 
however, not seen in lipedema in the absence of 
obesity. However, they also showed altered fat 
distribution72.
Fat-specific Sirt6 knockout mice are sensitized 
to high-fat diet–induced obesity resulting in adi-
pocyte hypertrophy caused by compromised lip-
olytic activity due to the decreased expression of 
the lipolytic enzyme, adipose tissue triglyceride 
lipase (ATGL). Fat-specific Sirt6 KO also showed 
increased inflammation in adipose tissue, which 
contributes to insulin resistance in high-fat diet–
fed mice. These findings are consistent with the 
reduced expression of SIRT6 and ATGL observed 
in obese patients73. Recently, in humans, it has 
been observed that, in the subcutaneous adipose 
tissue, increased body mass index modifies the 
expression of the genes encoding sirtuins and 
their target genes, which are metabolic regulators 
of adipose tissue74. Interestingly, SIRT6 is widely 
expressed in retinoblastomas, a tumor that in 4% 
of cases shows the presence of lipomatosis.
FGF21 improves systemic insulin sensitivity 
by promoting the healthy expansion of subcuta-
neous adipose tissue. FGF21 knockout mice show 
less subcutaneous adipose tissue and are more 
insulin-resistant when fed with a high-fat diet. 
Moreover, serum FGF21 levels positively cor-
relate with the subcutaneous adipose tissue area 
in insulin-sensitive obese individuals75.
IL18 receptor 1- knockout mice have an in-
creased susceptibility to dietary-induced obesity. 
It was observed by Pazos et al76 that Il18 knockout 
mice were extremely dietary obesity-prone and did 
not develop diet-induced thermogenesis as assessed 
by brown adipose tissue and white adipose tissue 
Ucp1 mRNA levels. Interestingly, women with li-
pedema have reported cold areas in fat tissue.
PANX1 encodes a glycoprotein, pannexin 1, 
which plays a key role in regulating the formation 
of adipocytes and fat accumulation. Increased adi-
pocyte size and decreased adipocyte numbers were 
observed in subcutaneous fat of the Panx1 knockout 
mice compared to wild-type mice. Knockout mice 
lacking Panx1 gene have significantly greater total 
fat mass and reduced lean mass under a normal diet. 
By metabolic cage data, it was observed that Panx1 
knockout mice on a high-fat diet display significant-
ly increased activity levels, higher ambulatory activ-
ity, and reduced sleep duration with respect to wild 
type mice. Absence of the Panx1 protein also leads 
to increased insulin and blood glucose levels, which 
increase the risk of type 2 diabetes77.
causes a rare atypical FPLD by inducing exces-
sive lipolysis in certain adipose tissue depots66.
Candidate Genes from Genome-Wide 
Association and Animal Models Studies
Several types of studies have been conduct-
ed to identify candidate genes associated with 
lipedema: genome-wide association studies 
(GWAS) and studies on animal models.
LYPLAL1, TBX15, HOXC13, RSPO3, CPEB4, 
VEGFA, STAB1, GRB14, ZNRF3, and PIGC have 
been associated with subcutaneous adipose de-
pots by genome-wide association studies and con-
firmed by functional analyses. The association of 
these genes with body fat distribution is indepen-
dent of any effects of BMI and/or obesity, demon-
strating genetic control of body fat distribution, 
distinct from that of overall adiposity67,68.
ATXN1 and UBE2E2 play a physiological role 
in adipogenesis. In support of these genes as can-
didate genes for lipedema, seven loci associated 
with ectopic fat traits have been identified in a 
multi-ethnic, sample-size-weighted, fixed-effects 
genome-wide association meta-analysis study 
at the genomic level: ATXN1, UBE2E2, EBF1, 
RREB1, GSDMB, GRAMD3, ENSA. Functional 
analyses of ATXN1 and UBE2E showed that loss 
of Atxn1 or Ube2e2 in primary mouse adipose 
progenitor cells hindered differentiation of adipo-
cytes69.
VEGFR3 signaling is fundamental for the 
development and maintenance of the lymphatic 
vascular system70. VEGFR3 is associated with the 
development of lymphedema in humans71. Mice 
with VEGFR-3 gene heterozygous inactivating 
missense mutations have hypoplastic dermal 
lymphatics and thickening of the subcutaneous 
adipose tissue. Vascular endothelial growth fac-
tors VEGFC and VEGFD stimulate lymphangio-
genesis, whereas VEGFR3 is a potent inhibitor of 
VEGFC/VEGFD signaling. In the skin of trans-
genic mice, VEGFR3 inhibits fetal lymphangio-
genesis and induces regression of already formed 
lymphatic vessels, though the blood vasculature 
remains normal. The transgenic K14-VEGFR3–
Ig mice show, besides other features, increased 
deposition of subcutaneous fat70.
The ablation of PRDM16 in mice adipocytes 
has significant reductions in thermogenic gene 
expression and O2 consumption of white adi-
pose tissue, both in the basal state and following 
stimulation with cold and β3-adrenergic agonist 
treatment resulting in marked enlargement of 
the subcutaneous adipose tissue. These animals 
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nous insufficiency82. In some cases, the MRI anal-
ysis of excised lipomatosis nodules revealed that 
they were angiolipomas identifiable with MRI83. 
In another work, using MRI in women with li-
pedema, higher levels of sodium were found in 
the fat tissue with even early stage lipedema com-
pared to controls84 suggesting a strong role for 
lymphatic dysfunction in lipedema85.
The Streeten test may be considered as a 
functional test to differentiate lipedema from 
lymphedema2. General blood tests are important 
because patients with lipedema may have diseas-
es that are responsible for the worsening of their 
symptoms2.
Characterization of family history and clinical 
phenotype will be fundamental for genetic test-
ing in lipedema, as a causal mutation is thought 
to be important in this disease25. Currently, ge-
netic tests and guidelines for the molecular di-
agnosis of lipedema are not available. However, 
genetic testing to exclude overlapping conditions 
or syndromic lipedema would be of fundamental 
importance. Lipedema is often misdiagnosed be-
cause of its similarity with primary lymphedema, 
Mendelian non-syndromic obesity, and general-
ized and partial lipodystrophies. We propose the 
use of a genetic test based on the next generation 
sequencing of a panel of genes that could be in-
volved in syndromic lipedema and are involved 
in phenotypically overlapping disorders (obesity, 
lymphedema, and lipodystrophies) with similar 
adiposity to exclude these pathologies. After the 
exclusion of the presence of known pathogenic 
mutations in both blood (germline mutations) and 
affected tissue (somatic mutations), whole exome/
genome sequencing would be required to identify 
the still-unknown gene (2). In Figure 2, a possible 
and ideal diagnostic genetic test for lipedema is 
schematized.
Conclusions
Lipedema is a very disabling disease that affects 
the quality of life, but unfortunately, it may be easily 
misdiagnosed1. It belongs to a spectrum of the lo-
calized painful depots of subcutaneous adipose tis-
sue (adiposis dolorosa) that includes a generalized/
localized/diffuse/nodular form of Dercum disease, 
Madelung disease (multiple symmetric lipomatosis), 
partial lipodystrophy, familial multiple lipomatosis, 
and lymphedema. A timely and accurate diagnosis 
of lipedema is essential for early intervention and 
treatment of the disease to prevent the development 
SCD1 encodes an enzyme that catalyzes the 
synthesis of monounsaturated fatty acids and is an 
important regulator of whole-body energy homeo-
stasis. Knockout mice lacking Scd1 gene display 
marked sebaceous gland hypoplasia, depletion of 
sebaceous lipids, increased energy expenditure 
and protection from high-fat diet-induced obesity, 
and severe cold intolerance. mRNA levels of SCD1 
in subcutaneous adipose tissue correlate with BMI 
in morbidly obese subjects78. SCD1 mRNA levels 
have not been tested in lipedema but loss of SCD1 
activity was inferred due to the lower levels of un-
saturated fatty acids from subcutaneous adipose 
tissue of people with fat disorders79.
PROX1 is a gene correlated to leaky lymphatic 
vessels as observed by studying mice with func-
tional inactivation of a single allele of this homeo-
box gene. PROX1 is fundamental for lymphatic 
vascular development and Prox1 knockout mice 
are obese. Prox1 haploinsufficiency results in 
subcutaneous and intra-abdominal fat accumula-
tion in mice80, a potential subclinical cause for the 
accumulation of lipedema fat tissue.
ZPF423 encodes a multi-zinc-finger transcrip-
tion factor expressed in preadipocytes and mature 
adipocytes in vivo and is responsible for the ter-
minal differentiation of subcutaneous white adi-
pose tissue. Knocking out Zfp423 in mice results 
in white-to-beige phenotypic adipocytes switch. 
When Zfp423 is removed from precursors and/or 
actively differentiating cells, there is a defect in 
the terminal differentiation of white adipocytes. 
The loss of lipid in the adipocytes in the absence 
of Zfp423 is due to lower expression of PPARγ 
and other adipocyte-selective genes. Therefore, 
ZFP423 has a fundamental role in the establish-
ment and maintenance of the white adipose lin-
eage81 and could be speculated to play a role in 
maintenance of lipedema fat.
Lipedema Diagnosis and Genetic Test 
The diagnosis of lipedema is mainly based on 
the medical history and physical examination of 
the patient2. Multiple imaging techniques such as 
ultrasound, magnetic resonance imaging (MRI) 
that allows identification of subclinical nodules, 
computed tomography, lymphoangioscintigra-
phy, indirect lymphangiography, and dual energy 
X-ray absorptiometry have all been applied in the 
diagnosis and study of lipedema. Fluorescence 
micrography makes it possible to detect multiple 
microaneurysms in lymphatic capillaries in the 
skin regions affected by lipedema not detectable 
in other pathologies, such as scleroderma and ve-
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known and there are no current reliable biomarkers 
or imaging modalities. Currently, the gene/s associ-
ated with primary lipedema are not known, whereas 
some genes associated with syndromic lipedema are 
known. Genome-wide association and animal mod-
els studies have made it possible to identify possible 
candidate genes and genetic pathways involved in 
the onset of lipedema. The advent of new molecular 
technologies will improve research and diagnostic 
of co-morbidities. For this purpose, it is important to 
develop a genetic test for lipedema based on increas-
ing knowledge of causative genes for other disorders 
and rapid advances in genetic screening technolo-
gies. Lipedema is an inherited disease expressed 
mainly in females, with males serving as carriers27,86. 
Lipedema is a relatively poorly studied disease, in 
fact, the mechanisms concerning the etiopathogen-
esis and the genetics of lipedema are not yet fully 
Figure 2. Scheme of a possible and ideal diagnostic genetic test for genetic subcutaneous fat accumulation. 
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process, ensuring the possibility of more effective 
prevention and treatment with clear improvements 
in the management of lipedema patients. The de-
velopment of a genetic test containing candidate 
genes for lipedema and causative genes of dis-
eases that can be confused with lipedema will be 
fundamental to find the etiology of lipedema and 
to provide patients with more targeted care and 
follow-up. By analysis of the whole exome with 
NGS technology in the patient and their parents 
could allow identification of new candidate genes 
for lipedema87 but the phenotype must be clearly 
defined. A multidisciplinary approach and with 
different technologies would be needed. Under-
standing the molecular mechanisms underlying 
the onset of lipedema requires a multi-pronged 
approach based on, for instance, genome, tran-
scriptome and methylome studies. Hopefully, the 
use of NGS technologies will help clinicians clas-
sify people that meet the criteria for the adiposis 
dolorosa spectrum.
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